Privia Health Group, Inc.

Privia Health Group, Inc. (PRVA) Market Cap

Privia Health Group, Inc. has a market capitalization of $2.98B.

Price: $23.67

-0.19 (-0.80%)

Market Cap: 2.98B

NASDAQ · time unavailable

CEO: Parth Mehrotra

Sector: Healthcare

Industry: Medical - Healthcare Information Services

IPO Date: 2021-04-28

Website: https://www.priviahealth.com

Privia Health Group, Inc. (PRVA) - Company Information

Market Cap: 2.98B|Sector: Healthcare

Company Profile

Privia Health Group, Inc. functions as a national entity focused on empowering physicians throughout the United States. It partners with medical groups, health plans, and health systems, with the primary objective of optimizing physician practices, enhancing patient experiences, and appropriately compensating clinicians for care delivered both virtually and in person. To achieve this, Privia offers a comprehensive suite of services. These include technology and population health tools designed to streamline independent providers' workflows; a Management Services Organization (MSO) that alleviates administrative tasks, freeing providers to focus on clinical care; a single-TIN medical group, which bolsters payer negotiations, facilitates clinical integration, and aligns financial incentives; an Accountable Care Organization (ACO) designed to engage patients, reduce inefficient utilization, and improve care coordination and patient quality metrics, thereby advancing value-based care; and a network connecting providers with new patient populations and enabling custom contracts with purchasers and payers. Founded in 2007, the company's headquarters are located in Arlington, Virginia. Privia Health Group, Inc. was formerly a subsidiary of Brighton Health Group Holdings, LLC.

Analyst Sentiment

84%
Strong Buy

From 20 Active Polls

1Y Forecast: $29.50

▲ +24.6% Potential Upside

Consensus Target Metrics

Low Bound

$24

Median

$29

High Bound

$36

Average

$30

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$29.50
▲ +24.63% Upside
Low Target
$24.00
1% Risk
Median Target
$29.00
23% Mid
High Target
$36.00
52% Max
Consensus
Buy
20 / 22 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Market Cap ($M)2,9832,5542,9213,0572,8092,7082,3492,1792,040
Enterprise Value ($M)2,5722,1432,4512,6222,4262,2441,8631,7631,659
Price to Earnings Ratio (P/E)133.80208.2079.78111.36261.36187.08133.54151.75142.50
Price/Earnings-to-Growth Ratio (PEG)17.989.7930.5644.9225.4541.1083.54
Price to Sales Ratio (P/S)1.334.235.405.275.395.645.104.984.83
Price to Book Ratio (P/B)3.903.393.964.314.114.113.703.543.43
Price to Free Cash Flow Ratio (P/FCF)21.81-51.6022.9160.18352.41-112.5531.4165.7259.19
Enterprise Value to Sales (EV/Sales)3.554.534.524.654.674.044.033.93
Enterprise Value to EBITDA (EV/EBITDA)45.62170.23152.90134.87291.29223.29189.07180.39167.93
Debt to Equity Ratio-7.280.010.010.010.010.010.010.010.01

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 PRIVIA HEALTH GROUP INC (PRVA) — Investment Overview

🧩 Business Model Overview

Privia Health Group operates as a physician enablement platform focused on value-based care and payer-facing care management. The company’s core “how it works” centers on aligning incentives and infrastructure across independent physician practices: (1) technology and operational support for clinical documentation, care coordination, and performance reporting; (2) care management workflows that improve chronic-disease outcomes and reduce avoidable utilization; and (3) contracting capabilities that help practices participate in risk- and quality-based arrangements with payers. Over time, Privia’s model benefits from the operational integration of practices into a standardized ecosystem, allowing consistent measurement, reporting, and execution across a large footprint.

The practical outcome is a service delivery and data layer that reduces friction for practices to operate under modern reimbursement structures while giving payers greater confidence in quality metrics and cost-control performance.

💰 Revenue Streams & Monetisation Model

Monetisation is primarily driven by recurring fees for operational and technology support and by value-based care-related economics tied to quality and utilization. Revenue composition typically includes:

  • Recurring practice/technology support: ongoing subscription-style or per-unit arrangements for software-enabled services, administrative tooling, and care coordination capabilities.
  • Value-based and performance components: economics linked to outcomes, quality performance, and/or care delivery under risk or shared-savings frameworks.
  • Transactional services embedded within care delivery: services that scale with care volume and program participation, though the long-term goal is a higher mix of recurring, platform-driven economics.

Margin drivers generally relate to (1) the scalability of the technology and care management operating model, (2) the ability to manage medical cost trends through clinical protocols and analytics, and (3) operational leverage as the platform supports more practices and attributed lives without proportionate increases in overhead.

🧠 Competitive Advantages & Market Positioning

Moat: Switching costs and integrated ecosystem built around performance reporting.

  • High switching costs (workflow + operational integration): once a practice’s documentation, clinical workflows, performance tracking, and payer reporting processes run through Privia’s support layer, replacing the ecosystem is operationally disruptive and costly. The switching barrier is reinforced by the practical need to maintain continuity in reporting and care-management protocols.
  • Integrated ecosystem (data gravity + performance measurement): Privia’s platform standardizes clinical and operational processes, enabling consistent measurement of quality indicators and care patterns across practices. That standardization improves execution and makes it harder for competitors to replicate outcomes without comparable implementation depth.
  • Payer/customer “confidence” as a durable asset: consistent reporting and care-management execution under value-based arrangements can increase payer willingness to expand contracts, creating a reinforcing loop between performance and scaling opportunities.

Competitive benchmarking (primary peers):

  • Aledade (ACO enablement for independent physician practices): both pursue value-based care enablement, but Privia’s emphasis on integrating broader operational/technology support and scaling through a larger service ecosystem shapes its competitive profile.
  • Optum (UnitedHealth Group) (care delivery and value-based services): Optum competes with scale and payer relationships; Privia’s differentiator is enabling and standardizing physician practice operations in a manner tailored to smaller, fragmented care settings.
  • Oak Street Health (value-focused primary care delivery): Oak Street is more delivery-centric with clinic operations, while Privia leans toward practice enablement and payer-aligned infrastructure across a wider physician footprint.

Against these rivals, Privia’s positioning is centered on making independent practices operationally capable under value-based reimbursement through technology-enabled care management and performance reporting—an angle that depends less on owning fixed site capacity and more on scalable integration.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, Privia’s growth can be supported by durable demand drivers that favor platform-based value-based care enablement:

  • Secular shift toward value-based reimbursement: payers increasingly seek measurable quality and cost outcomes, raising demand for standardized care-management and reporting infrastructure.
  • Medicare Advantage and risk-based contracting expansion: as government and commercial payers broaden risk arrangements, physician support models that can operate under performance accountability gain relevance.
  • Chronic disease management needs: aging demographics and rising chronic-care utilization increase the value of structured care pathways, analytics, and proactive care coordination.
  • Data-driven care operations: the industry continues to move toward performance measurement, documentation quality, and outcome tracking—areas where integrated ecosystems can produce incremental efficiencies.
  • Practice fragmentation economics: the U.S. physician market remains fragmented; platform providers that can standardize operations across independent groups can expand through “onboard and replicate” implementations.

⚠ Risk Factors to Monitor

  • Regulatory and reimbursement risk: changes to CMS rules, Medicare Advantage risk adjustments, and value-based program design can alter economics, quality requirements, or the feasibility of risk-based participation.
  • Execution and integration risk: scaling physician practices requires disciplined onboarding, change management, and adherence to clinical and documentation protocols; underperformance can pressure margins and payer confidence.
  • Cybersecurity and data privacy: a technology-enabled healthcare model depends on robust protection of sensitive health information and continuity of digital operations.
  • Medical cost trend and risk-bearing economics: where contracts include risk or shared savings, adverse utilization or coding/documentation mismatches can reduce profitability.
  • Concentration and contract dynamics: payer contract terms and renewal outcomes can materially influence revenue mix and profitability.

📊 Valuation & Market View

Market valuation for healthcare services/platform models typically focuses on the durability and visibility of earnings, not just growth. Investors often benchmark on metrics such as EV/Revenue or EV/EBITDA, with premium valuation associated with:

  • Recurring revenue quality: higher recurring mix tied to services and technology support can stabilize results versus purely transactional models.
  • Evidence of operational leverage: improving margins as scale increases suggests the platform is producing sustainable cost efficiencies.
  • Quality/performance credibility: demonstrated execution under value-based arrangements can support multiple expansion through lower perceived contract-risk.
  • Managed lives / practice scale growth: scale can drive better unit economics when implementation costs do not rise proportionally.

Key valuation sensitivities usually include the pace of practice and contract expansion, the mix between recurring support and value-based performance components, and any changes in reimbursement policy that affect shared-savings or risk economics.

🔍 Investment Takeaway

Privia’s long-term case rests on a structural shift toward value-based care and on a defensible operating model that creates switching costs through workflow integration and data-driven performance measurement. The company’s integrated ecosystem can support scaled physician enablement while meeting payer demands for measurable quality and cost control. The investment merits align with sustained industry adoption of value-based contracting, tempered by reimbursement, execution, and medical cost trend risks that warrant ongoing monitoring.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for PRVA.

gurufocus.com2026-07-22

Privia Health Group Inc (PRVA) Shares Fall 3.6% -- What GF Score of 88 Tells Investors

On July 22, 2026, Privia Health Group Inc (PRVA) shares fell 3.6% today, bringing the current price to $25.37. Over the past 52 weeks, the stock has fluctuated

fool.com2026-07-12

What Does a Privia Health Insider's Sale of Company Shares for $3.6 Million Mean for Investors?

Former CEO Shawn Morris sold 135,498 shares on June 30 and July 1, 2026, generating proceeds of ~$3.57 million at a weighted average price around $26.32 per share. Morris' sale reduced direct ownership to 76,651 shares post-transaction.

globenewswire.com2026-07-07

Privia Health to Report Second Quarter 2026 Results on Thursday, August 6

ARLINGTON, Va., July 07, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced that it expects to release financial results for its second-quarter and six-month periods ended June 30, 2026 before market open on Thursday, August 6, 2026.

fool.com2026-06-08

Privia's CEO Just Sold 121,000 Shares for $2.7 Million

CEO Parth Mehrotra sold 121,086 shares directly for a total of ~$2.73 million at an average price of around $22.56 per share across two days ending May 12, 2026. This transaction represented 21.80% of Mehrotra's direct holdings prior to the sale, reducing his direct position to 434,357 shares.

gurufocus.com2026-06-04

A Look at Privia Health Group Inc (PRVA) After 3.4% Gain -- GF Value $27.19 vs Price $21.37

On June 04, 2026, Privia Health Group Inc (PRVA) shares rose 3.4% to a current price of $21.37. Over the past 52 weeks, the stock has traded between $18.77 and

fool.com2026-05-30

Is Privia Health Stock a Buy After Hedge Fund Rubicon Founders Added Over 175,000 Shares to Its Position?

Privia Health Group delivers technology-driven solutions to optimize physician practices and support value-based care nationwide.

globenewswire.com2026-05-28

Cross Keys Capital Advises Neurology Group of Bergen County in Its Partnership with Privia Health

Fort Lauderdale, May 28, 2026 (GLOBE NEWSWIRE) -- Cross Keys Capital, LLC, a leading independent investment banking firm providing M&A advisory services to physician group practices and healthcare services companies,is  pleased to announce it acted as the exclusive financial advisor to the Neurology Group of Bergen County (“NGBC”) in its partnership with Privia Health. Founded in 1973, the Neurology Group of Bergen County is one of the region's most respected independent neurology practices, serving the communities of Bergen County, New Jersey.

zacks.com2026-05-27

TBRG vs. PRVA: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical Info Systems sector might want to consider either TruBridge (TBRG) or Privia Health (PRVA). But which of these two stocks presents investors with the better value opportunity right now?

globenewswire.com2026-05-27

Privia Health Enters New Jersey

ARLINGTON, Va., May 27, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA), a national physician enablement company, announced it has signed a definitive agreement to enter the state of New Jersey in partnership with Neurology Group of Bergen County (NGBC), a practice with 25 adult and pediatric clinicians.

zacks.com2026-05-11

TBRG or PRVA: Which Is the Better Value Stock Right Now?

Investors interested in Medical Info Systems stocks are likely familiar with TruBridge (TBRG) and Privia Health (PRVA). But which of these two stocks presents investors with the better value opportunity right now?

marketbeat.com2026-05-08

Privia Health Group Q1 Earnings Call Highlights

Privia Health Group NASDAQ: PRVA reported a strong first quarter, with executives pointing to double-digit provider growth, a larger value-based care population and margin expansion as signs that the company's operating model continues to scale.

seekingalpha.com2026-05-08

Privia Health Group, Inc. (PRVA) Q1 2026 Earnings Call Transcript

Privia Health Group, Inc. (PRVA) Q1 2026 Earnings Call Transcript

zacks.com2026-05-07

Privia Health (PRVA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Privia Health (PRVA) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

zacks.com2026-05-07

Privia Health (PRVA) Misses Q1 Earnings Estimates

Privia Health (PRVA) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.08 per share. This compares to earnings of $0.03 per share a year ago.

globenewswire.com2026-05-07

Privia Health Reports First Quarter 2026 Financial Results

Privia Health Reports First Quarter 2026 Financial Results; Strong First Quarter Performance and Operating Execution; Reiterated Full-Year 2026 Guidance

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"PRVA reported Q1’26 revenue of $603.8M and net income of $3.1B (EPS $0.02). On a YoY basis, revenue rose from $480.1M in Q1’25 to $603.8M (+25.8% YoY), while net income increased from $4.2M to $3.1B (very large +~72,000% YoY). Sequentially (QoQ), revenue grew from $541.2M in Q4’25 to $603.8M (+11.6% QoQ), and net income jumped from $9.2M to $3.1B (up sharply QoQ). Profitability was mixed: operating income was only $7.4M (operating margin ~1.2%), yet net margin shows 5.1% in Q1’26, implying substantial below-the-line or one-time effects versus Q4’25 net margin of ~1.7%. Over the last four reported quarters, operating margins generally trended higher from Q2’25 (~0.6%) through Q4’25 (~2.1%), then remained modest in Q1’26 (~1.2%). Cash flow deteriorated materially in Q1’26, with operating cash flow of -$49.5M and free cash flow of -$49.5M, versus positive operating cash flow in Q4’25 (+$127.5M). Balance sheet strength remains notable for scale, with total assets ~ $1.42B and net cash (net debt -$410.5B shown) supported by very large cash & equivalents ($419.5B). Total shareholder return is not captured by buybacks/dividends (none reported). Market performance shows the stock at $24.02 with only +0.63% over 1 year—momentum is not strong. Analyst valuation context includes a consensus target of ~$31.67 versus $24.02 current."

Revenue Growth

Positive

Revenue increased to $603.8M in Q1’26 (+25.8% YoY) and rose +11.6% QoQ from $541.2M in Q4’25, indicating accelerating top-line momentum.

Profitability

Caution

Operating margin was modest (~1.2%) in Q1’26; despite net income surging to $3.1B, the pattern suggests net results may be driven by below-operating effects. Prior quarters showed lower operating margins (Q2’25 ~0.6%, Q4’25 ~2.1%).

Cash Flow Quality

Neutral

Q1’26 operating cash flow was -$49.5M (free cash flow -$49.5M), versus +$127.5M in Q4’25—quality weakened sequentially.

Leverage & Balance Sheet

Neutral

Total assets increased to ~$1.42B from ~$1.37B QoQ. Liquidity appears very strong with cash & equivalents of ~$419.5B; debt is low (short-term debt ~$2.1B, long-term debt ~$6.9B). Equity is sizable (total stockholders’ equity ~$753.1M).

Shareholder Returns

Caution

No dividends or buybacks reported. Total return is therefore primarily dependent on price; 1Y performance is only +0.63% (no >20% momentum boost).

Analyst Sentiment & Valuation

Neutral

Consensus target is ~$31.67 versus current ~$24.02 (upside implied). Price/earnings metrics appear difficult to interpret given volatile earnings base in Q1’26.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

Privia reported strong Q1 execution with clear operating leverage and continued growth in value-based attribution. Adjusted EBITDA rose 36.3% YoY to $36.7 million and EBITDA margin expanded 290 bps to 28.5% of care margin, alongside 14.6% YoY practice collections growth to $914.8 million. The growth engine remains provider density and value-based performance: implemented providers reached 5,535 (+13.6% YoY), while value-based attributed lives increased 26.5% YoY to 1.6 million. CMS Medicare momentum was especially strong, with CMS lives up 62% and MA and Medicaid attribution rising 20% and 36%, respectively. Management maintained full-year 2026 guidance but raised the attributed-lives range, implying ~20% EBITDA growth at the $150 million midpoint and ~80% EBITDA-to-free-cash-flow conversion (excluding BD items). The Q&A reinforced that shared savings variability will be data-dependent, while AI and integration work (notably Evolent) are being positioned to support longer-term margin targets.

AI IconGrowth Catalysts

  • Implemented provider growth to 5,535 providers (+13.6% YoY) driving practice collections up 14.6% to $914.8 million
  • Value-based attributed lives grew to 1.6 million (+26.5% YoY), supported by implemented growth, attribution growth, and value-based care performance
  • Medicare-focused acceleration: CMS Medicare attributed lives up 62% YoY; Medicare Advantage +20% and Medicaid +36% YoY
  • Evolent ACO business contribution to attributed lives growth

Business Development

  • Addition of the Evolent ACO business (attributed lives contribution and integration described as ahead of schedule)
  • Discussion of contracting with 130+ commercial and government contracts (no specific contract names provided)
  • Commercial value-based partner execution referenced via payers (no payer names provided); OptumHealth cited as a comparable competitor in select geographies
  • Technology/AI ecosystem partnerships named: Google Suite & Gemini, Salesforce, Workday, Snowflake Coreex AI

AI IconFinancial Highlights

  • Adjusted EBITDA increased 36.3% YoY to $36.7 million; EBITDA margin expanded 290 bps to 28.5% of care margin
  • Practice collections increased 14.6% YoY to $914.8 million
  • Cash and debt: ended quarter with $219.5 million cash and no debt
  • Guidance maintained for full-year 2026; attributed lives guidance range raised based on strong Q1 attribution growth
  • Full-year guidance implies ~20% adjusted EBITDA growth at the $150 million midpoint and ~80% of full-year EBITDA converting to free cash flow (excluding BD line items)

AI IconCapital Funding

  • Noncontrolling interest transaction: ~$11 million NCI repurchase in the quarter (minority interest acquired in certain markets) expected to improve cash flow and net income
  • Ended Q1 with $219.5 million cash and no debt
  • Buyback not explicitly quantified; management discussed general flexibility to return capital if stock price is below intrinsic value; preference is reinvest/compound with balance-sheet acquisitions

AI IconStrategy & Ops

  • Provider expansion visibility: sequential implemented providers grew +155 from year-end 2025; 15 states using single-TIN model plus additional markets with ACO-only model
  • Cross-sell execution post-acquisition: Evolent integration emphasized (tech stack integrated and provider-facing implementation underway); sales cycles cited as 3–6 months with implementation 4–5 to 6 months
  • Technology org change: new Chief Technology Officer Konda joined from Optum Insights; longtime CTO Chris Foy retired
  • AI roadmap across 3 buckets (Privia Enterprise, care center operations, and care delivery) including examples: prior auth, autonomous coding, referral management; care gap closures, chart prep, scheduling, agentic patient outreach/engagement; clinical decision support and accurate coding
  • Commercial risk posture described as partial risk with corridors; management noted not taking significant downside risk currently due to open-access structure

AI IconMarket Outlook

  • 2026 guidance metrics reiterated; attributed lives range increased at year-end due to strong Q1 attribution growth
  • Midpoint target: ~$150 million implies ~20% adjusted EBITDA growth; target ~80% EBITDA-to-free-cash-flow conversion as the company becomes a full cash taxpayer
  • No new business development assumed in guidance (per CFO); reliance on pipeline/existing market expansion described

AI IconRisks & Headwinds

  • Shared savings variability: management indicated guidance is maintained because it is early in the year; shared savings may not be flat YoY if current trends hold, but prior-period adjustments could affect outcomes
  • Regulatory/program risk around Medicare Advantage (V28) and capitated vs shared-risk contracting by ZIP code/risk pools; management emphasized shared-risk preference but acknowledged contracting varies by geography
  • Weather/respiratory utilization concern addressed: management stated no major swings in ambulatory/community utilization vs prior years; inpatient can vary more

Q&A: Analyst Interest

  • Guidance conservatism vs puts/takes: Management said it’s early in the year and their approach since going public is to keep executing quarterly, then adjust guidance as more data becomes available. They noted shared savings likely shouldn’t be flat YoY if trends continue, but prior-period items could affect current-year outcomes.
  • Medicare Advantage and capitated/subcapitation appetite under V28: Management reiterated long-term MA tailwinds from demographics and emphasized focus on the MA book (over 550,000 MA attributed lives across MSSP and Medicare Advantage). They prefer shared-risk over full capitation to avoid conflicts as payers adjust local designs and baseline trends; some books will remain capitated.
  • Technology/AI acceleration with new CTO: Management highlighted that Konda joined from Optum Insights and is replacing a retiring CTO. They laid out AI implementations across enterprise, care center operations, and care delivery, citing named platform partners (Google/Gemini, Salesforce, Workday, Snowflake Coreex AI). They tied AI initiatives to margin expansion expectations (guidance close to ~29% EBITDA to care margin).

Sentiment: POSITIVE

Note: This summary was synthesized by AI from the PRVA Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for PRVA.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (PRVA)

© 2026 Stock Market Info — Privia Health Group, Inc. (PRVA) Financial Profile